Pub Date : 2024-08-01DOI: 10.1177/15357597241260546
Heidi M. Munger Clary
[Box: see text]
[方框：见正文]
{"title":"Preventing Verbal Memory Decline: Anatomic Clues to Predict Risk of Laser Ablation Versus Resection?","authors":"Heidi M. Munger Clary","doi":"10.1177/15357597241260546","DOIUrl":"https://doi.org/10.1177/15357597241260546","url":null,"abstract":"[Box: see text]","PeriodicalId":11742,"journal":{"name":"Epilepsy Currents","volume":"55 1","pages":""},"PeriodicalIF":3.6,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141881664","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-08-01DOI: 10.1177/15357597241261917
Nicolas Gaspard
[Box: see text]
[方框：见正文]
{"title":"In-hospital Management of Status Epilepticus: Does Uniformity Mean Quality?","authors":"Nicolas Gaspard","doi":"10.1177/15357597241261917","DOIUrl":"https://doi.org/10.1177/15357597241261917","url":null,"abstract":"[Box: see text]","PeriodicalId":11742,"journal":{"name":"Epilepsy Currents","volume":"7 1","pages":""},"PeriodicalIF":3.6,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141881663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-25DOI: 10.1177/15357597241261463
Catherine A. Christian-Hinman
Seizures and epilepsy affect people of all sexes and genders. In the last several years, funding agency initiatives such as the U.S. National Institutes of Health policy on sex as a biological variable (SABV) have intended to encourage researchers to study both males and females from cell to tissue to organism and analyze and report the resulting data with sex as a factor. Preclinical epilepsy research, however, continues to be plagued by confusion regarding both the SABV policy and its implementation, reflecting similar beliefs in the larger neuroscience research community. This article aims to address some common misconceptions and provide practical tools and suggestions for preclinical epilepsy researchers in implementing SABV and analysis of the female ovarian cycle (estrous cycle in rodents) in their research programs, with a focus on studies using rodent models. Examples of recent publications in preclinical epilepsy research highlighting the value of incorporating SABV and information on the estrous cycle are included. The specifics of how best to address SABV and the estrous cycle can vary depending on the needs and goals of a particular research program, but an embrace of these physiological factors by the preclinical epilepsy research community promises to yield more rigorous research and improved treatment strategies for all people with epilepsy.
癫痫发作和癫痫对所有性别的人都有影响。在过去几年里，美国国立卫生研究院（U.S. National Institutes of Health）关于性别作为生物变量（SABV）的政策等资助机构倡议鼓励研究人员研究从细胞、组织到生物体的男性和女性，并分析和报告将性别作为一个因素的结果数据。然而，临床前癫痫研究仍然受到有关 SABV 政策及其实施的困惑的困扰，这反映了广大神经科学研究界的类似观点。本文旨在解决一些常见的误解，并为临床前癫痫研究人员在其研究计划中实施 SABV 和分析雌性卵巢周期（啮齿动物的发情周期）提供实用工具和建议，重点关注使用啮齿动物模型进行的研究。文中列举了临床前癫痫研究领域最近发表的论文，这些论文强调了将 SABV 和发情周期信息纳入研究的价值。如何最好地处理 SABV 和发情周期的具体细节可能因特定研究计划的需求和目标而异，但临床前癫痫研究界对这些生理因素的接受有望为所有癫痫患者带来更严谨的研究和更好的治疗策略。
{"title":"The Promise and Practicality of Addressing Sex as a Biological Variable and the Ovarian Cycle in Preclinical Epilepsy Research","authors":"Catherine A. Christian-Hinman","doi":"10.1177/15357597241261463","DOIUrl":"https://doi.org/10.1177/15357597241261463","url":null,"abstract":"Seizures and epilepsy affect people of all sexes and genders. In the last several years, funding agency initiatives such as the U.S. National Institutes of Health policy on sex as a biological variable (SABV) have intended to encourage researchers to study both males and females from cell to tissue to organism and analyze and report the resulting data with sex as a factor. Preclinical epilepsy research, however, continues to be plagued by confusion regarding both the SABV policy and its implementation, reflecting similar beliefs in the larger neuroscience research community. This article aims to address some common misconceptions and provide practical tools and suggestions for preclinical epilepsy researchers in implementing SABV and analysis of the female ovarian cycle (estrous cycle in rodents) in their research programs, with a focus on studies using rodent models. Examples of recent publications in preclinical epilepsy research highlighting the value of incorporating SABV and information on the estrous cycle are included. The specifics of how best to address SABV and the estrous cycle can vary depending on the needs and goals of a particular research program, but an embrace of these physiological factors by the preclinical epilepsy research community promises to yield more rigorous research and improved treatment strategies for all people with epilepsy.","PeriodicalId":11742,"journal":{"name":"Epilepsy Currents","volume":"111 1","pages":""},"PeriodicalIF":3.6,"publicationDate":"2024-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141775210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-05-30DOI: 10.1177/15357597241254274
Thomas J. Foutz
[Box: see text]
[方框：见正文]
{"title":"Forgotten Tides: A Novel Strategy for Bayesian Optimization of Neurostimulation","authors":"Thomas J. Foutz","doi":"10.1177/15357597241254274","DOIUrl":"https://doi.org/10.1177/15357597241254274","url":null,"abstract":"[Box: see text]","PeriodicalId":11742,"journal":{"name":"Epilepsy Currents","volume":"51 1","pages":""},"PeriodicalIF":3.6,"publicationDate":"2024-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141195509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-05-30DOI: 10.1177/15357597241255274
Anup D. Patel, Charuta Joshi, Rohit Das, John M. Stern, Susan T. Herman, Barry E. Gidal
Objective:Telehealth in epilepsy care is not new. During the COVID-19 public health emergency, telehealth became more readily used to deliver epilepsy care. However, a summarized guidance of use in caring for people with epilepsy utilizing telehealth is needed.Methods:Existing literature was reviewed to provide guidance on various aspects of telehealth. Billing aspects are reviewed. Recommendations and considerations along with benefits and barriers to telehealth are provided.Results:Telehealth can be a preferred delivery route of care for people with epilepsy in specific situations. Examples include psychiatric complaints, medication management, and follow-up visits for noncomplicated epilepsy care. In addition, telehealth is useful for patients who need postoperative visits, are not able to travel, or live in residential facilities. In-person care may be more suitable for patients who are medically complex, have language barriers or difficulty with resource access, hearing impaired, or have neurostimulation devices where remote monitoring or programming options are infeasible.Discussion:Telehealth care for people with epilepsy can be a useful and important method of care delivery. It should remain an option for providers to use in epilepsy clinical care. It is important for the neurology provider to understand the benefits, billing, and barriers to providing telehealth.
{"title":"The Tell on Telehealth","authors":"Anup D. Patel, Charuta Joshi, Rohit Das, John M. Stern, Susan T. Herman, Barry E. Gidal","doi":"10.1177/15357597241255274","DOIUrl":"https://doi.org/10.1177/15357597241255274","url":null,"abstract":"Objective:Telehealth in epilepsy care is not new. During the COVID-19 public health emergency, telehealth became more readily used to deliver epilepsy care. However, a summarized guidance of use in caring for people with epilepsy utilizing telehealth is needed.Methods:Existing literature was reviewed to provide guidance on various aspects of telehealth. Billing aspects are reviewed. Recommendations and considerations along with benefits and barriers to telehealth are provided.Results:Telehealth can be a preferred delivery route of care for people with epilepsy in specific situations. Examples include psychiatric complaints, medication management, and follow-up visits for noncomplicated epilepsy care. In addition, telehealth is useful for patients who need postoperative visits, are not able to travel, or live in residential facilities. In-person care may be more suitable for patients who are medically complex, have language barriers or difficulty with resource access, hearing impaired, or have neurostimulation devices where remote monitoring or programming options are infeasible.Discussion:Telehealth care for people with epilepsy can be a useful and important method of care delivery. It should remain an option for providers to use in epilepsy clinical care. It is important for the neurology provider to understand the benefits, billing, and barriers to providing telehealth.","PeriodicalId":11742,"journal":{"name":"Epilepsy Currents","volume":"26 9-10 1","pages":""},"PeriodicalIF":3.6,"publicationDate":"2024-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141198506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-05-28DOI: 10.1177/15357597241253500
Wesley T. Kerr, Barry Gidal, Sean N. Avedissian, Cara McAnaney, Jo M. Wilmshurst, Brian S. Eley, Sarah Eyal, Sasha Alick-Lindstrom
The prevention of human immunodeficiency virus (HIV) infection has recently emphasized the use of pre- and post-exposure prophylaxis (PrEP and PEP), both of which were highly effective in prevention of HIV infection. Since the last published guidance regarding the cotreatment of people with anti-seizure medications (ASM) and antiretroviral treatments (ARTs) in 2012, both fields have numerous new medication options. Historically, cotreatment of HIV and seizures could be challenging with increased risk of virologic failure and barriers in access to health care due to global availability, social determinants of health, and stigma of both HIV and seizures. In this narrative review, we describe the data-driven and expected bidirectional pharmacokinetic (PK) interactions between guideline-based PrEP and PEP treatment and ASM, as well as overlapping side effects. There are many ASMs with no known interaction with PrEP or PEP regimens. The interactions focus on enzyme inducing ASMs, valproate, and lamotrigine. Most prominently, enzyme inducing ASMs lower serum levels of tenofovir-containing PrEP regimens and elements of PEP (dolutegravir, raltegravir, and ritonavir), which increased risk of virologic treatment failure in people with HIV but have unclear clinical significance on the effectiveness of PrEP and PEP. In addition, ritonavir treatment in PEP may significantly lower lamotrigine serum levels even during the 4 weeks of treatment, which may increase risk for breakthrough seizures during PEP and skin reactions after discontinuation of ritonavir. In addition to PK interactions, overlapping side effects are common including osteopenia, hepatic toxicity, and other gastrointestinal effects. This narrative review aims to be a resource for all clinicians prescribing ASMs so that they can create a welcoming environment to enable successful treatment of seizures and reduce the risk of HIV infection in people at risk. In addition, we highlight knowledge gaps and areas of unmet need that can be addressed with future studies.
近来，人类免疫缺陷病毒（HIV）感染的预防工作强调使用暴露前和暴露后预防疗法（PrEP 和 PEP），这两种疗法在预防 HIV 感染方面都非常有效。自上一次于 2012 年发布有关抗癫痫药物（ASM）和抗逆转录病毒疗法（ARTs）联合治疗的指南以来，这两个领域都有了许多新的药物选择。从历史上看，HIV 和癫痫发作的联合治疗可能具有挑战性，因为病毒学失败的风险会增加，而且由于全球可用性、健康的社会决定因素以及对 HIV 和癫痫发作的污名化等原因，在获得医疗保健服务方面存在障碍。在这篇叙述性综述中，我们描述了以数据为依据、基于指南的 PrEP 和 PEP 治疗与 ASM 之间预期的双向药代动力学（PK）相互作用，以及重叠的副作用。有许多 ASM 与 PrEP 或 PEP 方案之间没有已知的相互作用。相互作用主要集中在酶诱导型 ASM、丙戊酸钠和拉莫三嗪。最突出的是，酶诱导型 ASMs 会降低含替诺福韦的 PrEP 方案和 PEP 药物（多替拉韦、拉替拉韦和利托那韦）的血清水平，从而增加 HIV 感染者病毒学治疗失败的风险，但对 PrEP 和 PEP 的有效性的临床意义尚不明确。此外，PEP 中的利托那韦治疗可能会显著降低拉莫三嗪的血清水平，即使在 4 周的治疗期间也是如此，这可能会增加 PEP 期间出现突破性癫痫发作和停用利托那韦后出现皮肤反应的风险。除了 PK 相互作用外，重叠的副作用也很常见，包括骨质疏松、肝毒性和其他胃肠道反应。这篇叙述性综述旨在为所有开具 ASMs 处方的临床医生提供资源，以便他们能够创造一个良好的环境，成功治疗癫痫发作并降低高危人群感染 HIV 的风险。此外，我们还强调了知识差距和尚未满足需求的领域，这些都可以通过未来的研究加以解决。
{"title":"Pre- and Post-Exposure Prophylaxis for HIV in Patients Taking Anti-Seizure Medications","authors":"Wesley T. Kerr, Barry Gidal, Sean N. Avedissian, Cara McAnaney, Jo M. Wilmshurst, Brian S. Eley, Sarah Eyal, Sasha Alick-Lindstrom","doi":"10.1177/15357597241253500","DOIUrl":"https://doi.org/10.1177/15357597241253500","url":null,"abstract":"The prevention of human immunodeficiency virus (HIV) infection has recently emphasized the use of pre- and post-exposure prophylaxis (PrEP and PEP), both of which were highly effective in prevention of HIV infection. Since the last published guidance regarding the cotreatment of people with anti-seizure medications (ASM) and antiretroviral treatments (ARTs) in 2012, both fields have numerous new medication options. Historically, cotreatment of HIV and seizures could be challenging with increased risk of virologic failure and barriers in access to health care due to global availability, social determinants of health, and stigma of both HIV and seizures. In this narrative review, we describe the data-driven and expected bidirectional pharmacokinetic (PK) interactions between guideline-based PrEP and PEP treatment and ASM, as well as overlapping side effects. There are many ASMs with no known interaction with PrEP or PEP regimens. The interactions focus on enzyme inducing ASMs, valproate, and lamotrigine. Most prominently, enzyme inducing ASMs lower serum levels of tenofovir-containing PrEP regimens and elements of PEP (dolutegravir, raltegravir, and ritonavir), which increased risk of virologic treatment failure in people with HIV but have unclear clinical significance on the effectiveness of PrEP and PEP. In addition, ritonavir treatment in PEP may significantly lower lamotrigine serum levels even during the 4 weeks of treatment, which may increase risk for breakthrough seizures during PEP and skin reactions after discontinuation of ritonavir. In addition to PK interactions, overlapping side effects are common including osteopenia, hepatic toxicity, and other gastrointestinal effects. This narrative review aims to be a resource for all clinicians prescribing ASMs so that they can create a welcoming environment to enable successful treatment of seizures and reduce the risk of HIV infection in people at risk. In addition, we highlight knowledge gaps and areas of unmet need that can be addressed with future studies.","PeriodicalId":11742,"journal":{"name":"Epilepsy Currents","volume":"16 1","pages":""},"PeriodicalIF":3.6,"publicationDate":"2024-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141168234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-05-13DOI: 10.1177/15357597241253414
Danielle M. Andrade
[Box: see text]
[方框：见正文]
{"title":"Are We Doing Enough to Prevent SUDEP?","authors":"Danielle M. Andrade","doi":"10.1177/15357597241253414","DOIUrl":"https://doi.org/10.1177/15357597241253414","url":null,"abstract":"[Box: see text]","PeriodicalId":11742,"journal":{"name":"Epilepsy Currents","volume":"116 1","pages":""},"PeriodicalIF":3.6,"publicationDate":"2024-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140932836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-05-13DOI: 10.1177/15357597241253429
Anthony L. Fine
[Box: see text][Box: see text]
[方框：见正文][方框：见正文]
{"title":"Through the Lens: Insights Into Sudden Death","authors":"Anthony L. Fine","doi":"10.1177/15357597241253429","DOIUrl":"https://doi.org/10.1177/15357597241253429","url":null,"abstract":"[Box: see text][Box: see text]","PeriodicalId":11742,"journal":{"name":"Epilepsy Currents","volume":"188 1","pages":""},"PeriodicalIF":3.6,"publicationDate":"2024-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140932655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-05-13DOI: 10.1177/15357597241253508
Peter Widdess-Walsh
[Box: see text]
[方框：见正文]
{"title":"Over the Limit; Long-Term Seizure and Mortality Risk in Alcohol Withdrawal Seizures","authors":"Peter Widdess-Walsh","doi":"10.1177/15357597241253508","DOIUrl":"https://doi.org/10.1177/15357597241253508","url":null,"abstract":"[Box: see text]","PeriodicalId":11742,"journal":{"name":"Epilepsy Currents","volume":"29 1","pages":""},"PeriodicalIF":3.6,"publicationDate":"2024-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140932940","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-05-13DOI: 10.1177/15357597241251709
Juliet Knowles
[Box: see text]
[方框：见正文]
{"title":"Attentional Deficits and Absence Epilepsy: A Tale of 2 Interneuronopathies","authors":"Juliet Knowles","doi":"10.1177/15357597241251709","DOIUrl":"https://doi.org/10.1177/15357597241251709","url":null,"abstract":"[Box: see text]","PeriodicalId":11742,"journal":{"name":"Epilepsy Currents","volume":"131 1","pages":""},"PeriodicalIF":3.6,"publicationDate":"2024-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140932632","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：